Last reviewed · How we verify
SB773812
At a glance
| Generic name | SB773812 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SPECT Study With SB-773812 In Schizophrenic Patients (PHASE1)
- A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets. (PHASE1)
- Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812 (PHASE1)
- SB-773812 Administered In Adults With Schizophrenia (PHASE2)
- In-Patient Study In Schizophrenic Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB773812 CI brief — competitive landscape report
- SB773812 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI